FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1966455897> ?p ?o ?g. }

• W1966455897 endingPage "1414" @default.
• W1966455897 startingPage "1406" @default.
• W1966455897 abstract "In addition to the mutational status of KRAS, the epidermal growth factor receptor (EGFR) ligands amphiregulin (AREG) and epiregulin (EREG) might function as bona fide biomarkers of cetuximab (Ctx) sensitivity for most EGFR-driven carcinomas.Lentivirus-delivered small hairpin RNAs were employed to specifically reduce AREG or EREG gene expression in wild-type KRAS A431 squamous cell carcinoma cells. Colony-forming assays were used to monitor the impact of AREG and EREG knockdown on Ctx efficacy. Amphiregulin and EREG protein expression levels were assessed by quantitative ELISA in parental A431 cells and in pooled populations of A431 cells adapted to grow in the presence of Ctx. A phosphoproteomic platform was used to measure the relative level of phosphorylation of 42 distinct receptor tyrosine kinases before and after the acquisition of resistance to Ctx.Stable gene silencing of either ligand was found to notably reduce the expression of the other ligand. Parental A431 cells with normal expression levels of AREG/EREG exhibited significantly increased growth inhibition in response to Ctx, compared with derivatives that are engineered to produce minimal AREG/EREG. The parental A431 cells acutely treated with Ctx exhibited reduced basal expression levels of AREG/EREG. Pooled populations of Ctx-resistant A431 cells expressed significantly lower levels of AREG/EREG and were insensitive to the downregulatory effects of Ctx. Phosphoproteomic screen identified a remarkable hyperactivation of FGFR3 in Ctx-resistant A431 cells, which gained sensitivity to the cytotoxic and apoptotic effects of the FGFR3 TK inhibitor PD173074. The A431 parental cells acutely treated with Ctx rapidly activated FGFR3 and their concomitant exposure to Ctx and PD173074 resulted in synergistic apoptosis.Cross-suppression of AREG/EREG expression may explain the tight co-expression of AREG and EREG, as well as their tendency to be more highly expressed than other EGFR ligands to determine Ctx efficacy. The positive selection for Ctx-resistant tumour cells exhibiting AREG/EREG cross-suppression may have an important role in the emergence of Ctx resistance. As de-repression of FGFR3 activity rapidly replaces the loss of EGFR-ligand signalling in terms of cell proliferation and survival, combinations of Ctx and FGFR3-targeted drugs may be a valuable strategy to enhance the efficacy of single Ctx while preventing or delaying acquired resistance to Ctx." @default.
• W1966455897 created "2016-06-24" @default.
• W1966455897 creator A5014700626 @default.
• W1966455897 creator A5017248208 @default.
• W1966455897 creator A5025874415 @default.
• W1966455897 creator A5030166947 @default.
• W1966455897 creator A5040178054 @default.
• W1966455897 creator A5040427139 @default.
• W1966455897 creator A5053116088 @default.
• W1966455897 creator A5059910653 @default.
• W1966455897 creator A5077187730 @default.
• W1966455897 date "2012-04-01" @default.
• W1966455897 modified "2023-10-18" @default.
• W1966455897 title "Cross-suppression of EGFR ligands amphiregulin and epiregulin and de-repression of FGFR3 signalling contribute to cetuximab resistance in wild-type KRAS tumour cells" @default.
• W1966455897 cites W1798216587 @default.
• W1966455897 cites W1994075309 @default.
• W1966455897 cites W1995457482 @default.
• W1966455897 cites W2000092807 @default.
• W1966455897 cites W2003278673 @default.
• W1966455897 cites W2014457594 @default.
• W1966455897 cites W2016315875 @default.
• W1966455897 cites W2041777830 @default.
• W1966455897 cites W2041798076 @default.
• W1966455897 cites W2087468199 @default.
• W1966455897 cites W2101555865 @default.
• W1966455897 cites W2106391833 @default.
• W1966455897 cites W2110803737 @default.
• W1966455897 cites W2132431231 @default.
• W1966455897 cites W2138939757 @default.
• W1966455897 cites W2140334822 @default.
• W1966455897 cites W2168213749 @default.
• W1966455897 cites W2171583003 @default.
• W1966455897 cites W2602090891 @default.
• W1966455897 doi "https://doi.org/10.1038/bjc.2012.103" @default.
• W1966455897 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3326676" @default.
• W1966455897 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22491422" @default.
• W1966455897 hasPublicationYear "2012" @default.
• W1966455897 type Work @default.
• W1966455897 sameAs 1966455897 @default.
• W1966455897 citedByCount "39" @default.
• W1966455897 countsByYear W19664558972013 @default.
• W1966455897 countsByYear W19664558972014 @default.
• W1966455897 countsByYear W19664558972015 @default.
• W1966455897 countsByYear W19664558972016 @default.
• W1966455897 countsByYear W19664558972017 @default.
• W1966455897 countsByYear W19664558972018 @default.
• W1966455897 countsByYear W19664558972019 @default.
• W1966455897 countsByYear W19664558972020 @default.
• W1966455897 countsByYear W19664558972021 @default.
• W1966455897 countsByYear W19664558972023 @default.
• W1966455897 crossrefType "journal-article" @default.
• W1966455897 hasAuthorship W1966455897A5014700626 @default.
• W1966455897 hasAuthorship W1966455897A5017248208 @default.
• W1966455897 hasAuthorship W1966455897A5025874415 @default.
• W1966455897 hasAuthorship W1966455897A5030166947 @default.
• W1966455897 hasAuthorship W1966455897A5040178054 @default.
• W1966455897 hasAuthorship W1966455897A5040427139 @default.
• W1966455897 hasAuthorship W1966455897A5053116088 @default.
• W1966455897 hasAuthorship W1966455897A5059910653 @default.
• W1966455897 hasAuthorship W1966455897A5077187730 @default.
• W1966455897 hasBestOaLocation W19664558971 @default.
• W1966455897 hasConcept C121608353 @default.
• W1966455897 hasConcept C1491633281 @default.
• W1966455897 hasConcept C153911025 @default.
• W1966455897 hasConcept C170493617 @default.
• W1966455897 hasConcept C2776362946 @default.
• W1966455897 hasConcept C2777968868 @default.
• W1966455897 hasConcept C2779438470 @default.
• W1966455897 hasConcept C2779998722 @default.
• W1966455897 hasConcept C2780806702 @default.
• W1966455897 hasConcept C2781018059 @default.
• W1966455897 hasConcept C29537977 @default.
• W1966455897 hasConcept C2994460389 @default.
• W1966455897 hasConcept C47170353 @default.
• W1966455897 hasConcept C502942594 @default.
• W1966455897 hasConcept C526805850 @default.
• W1966455897 hasConcept C54355233 @default.
• W1966455897 hasConcept C55493867 @default.
• W1966455897 hasConcept C81885089 @default.
• W1966455897 hasConcept C86803240 @default.
• W1966455897 hasConceptScore W1966455897C121608353 @default.
• W1966455897 hasConceptScore W1966455897C1491633281 @default.
• W1966455897 hasConceptScore W1966455897C153911025 @default.
• W1966455897 hasConceptScore W1966455897C170493617 @default.
• W1966455897 hasConceptScore W1966455897C2776362946 @default.
• W1966455897 hasConceptScore W1966455897C2777968868 @default.
• W1966455897 hasConceptScore W1966455897C2779438470 @default.
• W1966455897 hasConceptScore W1966455897C2779998722 @default.
• W1966455897 hasConceptScore W1966455897C2780806702 @default.
• W1966455897 hasConceptScore W1966455897C2781018059 @default.
• W1966455897 hasConceptScore W1966455897C29537977 @default.
• W1966455897 hasConceptScore W1966455897C2994460389 @default.
• W1966455897 hasConceptScore W1966455897C47170353 @default.
• W1966455897 hasConceptScore W1966455897C502942594 @default.
• W1966455897 hasConceptScore W1966455897C526805850 @default.
• W1966455897 hasConceptScore W1966455897C54355233 @default.
• W1966455897 hasConceptScore W1966455897C55493867 @default.
• W1966455897 hasConceptScore W1966455897C81885089 @default.

• next